CN116549402A - Pirenpazide fine particle composition, preparation method and application - Google Patents
Pirenpazide fine particle composition, preparation method and application Download PDFInfo
- Publication number
- CN116549402A CN116549402A CN202310840588.0A CN202310840588A CN116549402A CN 116549402 A CN116549402 A CN 116549402A CN 202310840588 A CN202310840588 A CN 202310840588A CN 116549402 A CN116549402 A CN 116549402A
- Authority
- CN
- China
- Prior art keywords
- solution
- preparation
- lactose
- mannitol
- binder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 36
- 239000010419 fine particle Substances 0.000 title claims abstract description 9
- 239000000853 adhesive Substances 0.000 claims abstract description 38
- 230000001070 adhesive effect Effects 0.000 claims abstract description 38
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 28
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 28
- 229930195725 Mannitol Natural products 0.000 claims abstract description 28
- 239000008101 lactose Substances 0.000 claims abstract description 28
- 239000000594 mannitol Substances 0.000 claims abstract description 28
- 235000010355 mannitol Nutrition 0.000 claims abstract description 28
- 239000011230 binding agent Substances 0.000 claims abstract description 25
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims abstract description 21
- 239000002994 raw material Substances 0.000 claims abstract description 16
- 239000000463 material Substances 0.000 claims abstract description 12
- 238000001035 drying Methods 0.000 claims abstract description 8
- 238000005469 granulation Methods 0.000 claims abstract description 6
- 230000003179 granulation Effects 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims description 28
- 239000002245 particle Substances 0.000 claims description 21
- 238000005086 pumping Methods 0.000 claims description 15
- 230000008569 process Effects 0.000 claims description 11
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 9
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 9
- 238000007873 sieving Methods 0.000 claims description 6
- 238000000889 atomisation Methods 0.000 claims description 5
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 4
- 238000009477 fluid bed granulation Methods 0.000 claims description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 239000001961 anticonvulsive agent Substances 0.000 claims description 3
- 239000003086 colorant Substances 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims description 3
- 229960003943 hypromellose Drugs 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 229940069328 povidone Drugs 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 235000012239 silicon dioxide Nutrition 0.000 claims description 2
- 239000004408 titanium dioxide Substances 0.000 claims description 2
- 229960003965 antiepileptics Drugs 0.000 claims 1
- 238000004090 dissolution Methods 0.000 abstract description 17
- RMHMFHUVIITRHF-UHFFFAOYSA-N pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 abstract description 7
- 229960004633 pirenzepine Drugs 0.000 abstract description 7
- 239000004480 active ingredient Substances 0.000 abstract description 6
- 239000008186 active pharmaceutical agent Substances 0.000 abstract description 4
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 37
- 238000009472 formulation Methods 0.000 description 13
- 230000000052 comparative effect Effects 0.000 description 11
- 230000006399 behavior Effects 0.000 description 9
- 239000008187 granular material Substances 0.000 description 7
- 239000013078 crystal Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000004503 fine granule Substances 0.000 description 6
- 238000011161 development Methods 0.000 description 5
- 235000019640 taste Nutrition 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000005550 wet granulation Methods 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000004530 micro-emulsion Substances 0.000 description 4
- 239000006191 orally-disintegrating tablet Substances 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010013911 Dysgeusia Diseases 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 235000019629 palatability Nutrition 0.000 description 3
- 230000002572 peristaltic effect Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000007908 dry granulation Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- MMWRGWQTAMNAFC-UHFFFAOYSA-N 1,2-dihydropyridine Chemical class C1NC=CC=C1 MMWRGWQTAMNAFC-UHFFFAOYSA-N 0.000 description 1
- 102000003678 AMPA Receptors Human genes 0.000 description 1
- 108090000078 AMPA Receptors Proteins 0.000 description 1
- 229940098747 AMPA receptor antagonist Drugs 0.000 description 1
- 239000000775 AMPA receptor antagonist Substances 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000020980 bad eating habits Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000001339 gustatory effect Effects 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000010583 slow cooling Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310840588.0A CN116549402B (en) | 2023-07-11 | 2023-07-11 | Pirenpazide fine particle composition, preparation method and application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310840588.0A CN116549402B (en) | 2023-07-11 | 2023-07-11 | Pirenpazide fine particle composition, preparation method and application |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116549402A true CN116549402A (en) | 2023-08-08 |
CN116549402B CN116549402B (en) | 2023-09-19 |
Family
ID=87493269
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310840588.0A Active CN116549402B (en) | 2023-07-11 | 2023-07-11 | Pirenpazide fine particle composition, preparation method and application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116549402B (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105287411A (en) * | 2015-09-22 | 2016-02-03 | 美吉斯制药(厦门)有限公司 | Perampanel dispersible tablet and preparation method thereof |
CN105640900A (en) * | 2014-11-11 | 2016-06-08 | 天津市汉康医药生物技术有限公司 | Perampanel medicinal composition |
WO2016172333A1 (en) * | 2015-04-21 | 2016-10-27 | Teva Pharmaceuticals International Gmbh | A solid state form of perampanel |
CN106389367A (en) * | 2016-11-16 | 2017-02-15 | 杭州朱养心药业有限公司 | Perampanel coated tablet pharmaceutical composition |
US20170173039A1 (en) * | 2014-04-02 | 2017-06-22 | Yale University | Compositions and methods to treat addiction |
-
2023
- 2023-07-11 CN CN202310840588.0A patent/CN116549402B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170173039A1 (en) * | 2014-04-02 | 2017-06-22 | Yale University | Compositions and methods to treat addiction |
CN105640900A (en) * | 2014-11-11 | 2016-06-08 | 天津市汉康医药生物技术有限公司 | Perampanel medicinal composition |
WO2016172333A1 (en) * | 2015-04-21 | 2016-10-27 | Teva Pharmaceuticals International Gmbh | A solid state form of perampanel |
CN105287411A (en) * | 2015-09-22 | 2016-02-03 | 美吉斯制药(厦门)有限公司 | Perampanel dispersible tablet and preparation method thereof |
CN106389367A (en) * | 2016-11-16 | 2017-02-15 | 杭州朱养心药业有限公司 | Perampanel coated tablet pharmaceutical composition |
Also Published As
Publication number | Publication date |
---|---|
CN116549402B (en) | 2023-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI795462B (en) | Pharmaceutical preparation excellent in light stability and dissolution property | |
EP3862318A1 (en) | Porous silica particle composition | |
CN102905707A (en) | Pharmaceutical preparation comprising phenylalanine derivative | |
TWI788557B (en) | Solid dosage form having excellent stability | |
CN105193763B (en) | A kind of hydrobromic acid Vortioxetine piece and preparation method thereof | |
CN104968335A (en) | Novel fast-dissolving granule formulation having improved solubility | |
CN103393617B (en) | Febustat tablet and preparation method thereof | |
EP3733167A1 (en) | Novel fine particle coating (drug-containing hollow particle and method for manufacturing same) | |
CN104523686A (en) | Acotiamide hydrochloride medicinal preparation and preparation method thereof | |
CN116549402B (en) | Pirenpazide fine particle composition, preparation method and application | |
JPWO2012036078A1 (en) | Drug-containing film-coated particles with unpleasant taste masked | |
CN114129528B (en) | Novel sildenafil citrate preparation with clinical advantages and preparation process and application thereof | |
TWI344376B (en) | Pharmaceutical composition having improved solubility and fluidity | |
CN109700773B (en) | Ticagrelor preparation composition and preparation method thereof | |
KR101761983B1 (en) | Fast dissolving oral thin film composite and preparing method thereof | |
CN105287412A (en) | Aripiprazole dispersible tablet and preparation method thereof | |
CN113041231A (en) | Tebipenem pivoxil fine granule composition and preparation method thereof | |
CN104721154A (en) | Norfloxacin glutamate freeze-dried powder injection medicine composition for injection | |
CN104337783B (en) | A kind of capecitabine tablet and preparation method thereof | |
CN113599366B (en) | Tenofovir disoproxil fumarate granules and preparation method thereof | |
CN106913535A (en) | A kind of DDP-4 inhibitor medicaments oral disintegrating tablet and preparation method thereof | |
CN112704740B (en) | Montelukast resin compound and preparation method and application thereof | |
CN118415997A (en) | Preparation method of pirenzepine fine granule | |
Khailkhura et al. | Orally disintegrating tablet: A review | |
CN117695255A (en) | Production process of loratadine oral instant film agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231024 Address after: 201815 building 16, No. 66, Huiyuan Road, Jiading District, Shanghai Patentee after: Zezheng (Shanghai) Biotechnology Co.,Ltd. Patentee after: SHANDONG HI-QUAL PHARMATECH CO.,LTD. Address before: Floor 4, Building D, Biomedical Innovation Park, No. 1, Lutai Avenue, High tech Zone, Zibo City, Shandong Province 255,035 Patentee before: SHANDONG HI-QUAL PHARMATECH CO.,LTD. |
|
TR01 | Transfer of patent right | ||
CP03 | Change of name, title or address |
Address after: 201815 building 16, No. 66, Huiyuan Road, Jiading District, Shanghai Patentee after: Shanghai Zezheng Pharmaceutical Technology Co.,Ltd. Country or region after: China Patentee after: SHANDONG HI-QUAL PHARMATECH CO.,LTD. Address before: 201815 building 16, No. 66, Huiyuan Road, Jiading District, Shanghai Patentee before: Shanghai Zezheng Biopharmaceutical Co.,Ltd. Country or region before: China Patentee before: SHANDONG HI-QUAL PHARMATECH CO.,LTD. Address after: 201815 building 16, No. 66, Huiyuan Road, Jiading District, Shanghai Patentee after: Shanghai Zezheng Biopharmaceutical Co.,Ltd. Country or region after: China Patentee after: SHANDONG HI-QUAL PHARMATECH CO.,LTD. Address before: 201815 building 16, No. 66, Huiyuan Road, Jiading District, Shanghai Patentee before: Zezheng (Shanghai) Biotechnology Co.,Ltd. Country or region before: China Patentee before: SHANDONG HI-QUAL PHARMATECH CO.,LTD. |
|
CP03 | Change of name, title or address |